A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut after Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Trial Identifier: 0892-CL-1002
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: March 2019
Primary Completion Date: October 2021
Study Completion Date: October 2021

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States of America, AR Little Rock, AR, United States of America, 72205
United States of America, CA Mountain View, CA, United States of America, 94090
United States of America, IL Chicago, IL, United States of America, 60637
United States of America, MA Boston, MA, United States of America, 02114
United States of America, NY New York, NY, United States of America, 10029
United States of America, OH Cincinnati, OH, United States of America, 45241
United States of America, WA Seattle, WA, United States of America, 98115